Patent · US Active

Lactam compound

US7468365B2 · kind B2 · utility

9Cited by

5References

15Claims

0Family size

Assignees

ELI LILLY AND COMPANY · US
Elan Corporation, Inc. · FR

Inventors

James E. Audia · Indianapolis, US
Benjamin Alan Diseroad · Martinsville, US
Varghese John · San Francisco, US
Lee H. Latimer · Oakland, US
Jeffrey S. Nissen · Indianapolis, US
Gregory Alan Stephenson · Fishers, US
Eugene D. Thorsett · Moss Beach, US
Jay Tung · Belmont, US

Key dates

Filing date	Jan 11, 2006
Grant date	Dec 23, 2008
Priority date	—
Expiry date	Oct 21, 2026

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/28
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present invention provides crystalline (N)-((S)-2-hydroxy-3-methyl-butyryl)-1-(L-alaninyl)-(S)-1-amino-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one, a crystalline anydrate and dihydrates thereof, compositions comprising (N)-((S)-2-hydroxy-3-methyl-butyryl)-1-(L-alaninyl)-(S)-1-amino-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one, its crystalline anhydrate or dihydrate, and methods for using the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.